MediciNova Inc.
4350 La Jolla Village Drive
Suite 950
San Diego,
CA 92122
United States - Map
Phone: 858-373-1500
Fax: 858-373-7000
Web Site: http://www.medicinova.com
| MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs principally in the United States. The companys development pipeline includes programs that are in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, interstitial cystitis, solid tumor cancers, generalized anxiety disorder/insomnia, preterm labor, and urinary incontinence. Its principal product development programs consist of MN-221, which is in Phase II clinical trial for the treatment of acute exacerbations of asthma; and MN-166 that has completed Phase II clinical trial for the treatment of multiple sclerosis. The companys other product development programs include MN-001, which completed Phase II/III clinical trial for the treatment of interstitial cystitis and an oral dosing formulation prototype for the treatment of bronchial asthma; MN-029 that completed second Phase I clinical trial for the treatment of solid tumors; MN-305, which completed a Phase II/III clinical trial for the treatment of generalized anxiety disorder and a Phase II clinical trial for the treatment of insomnia; MN-221 that completed a Phase I clinical trial for the treatment of preterm labor; and MN-246, a Phase I clinical trial completed product for the treatment of urinary incontinence. Its preclinical development products comprise MN-447 and MN-462 for the treatment of thrombotic disorders. The company was founded in 2000 and is headquartered in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Yuichi Iwaki Ph.D., 59
Co-Founder, Chief Exec. Officer, Pres and Exec. Director |
N/A
| N/A | Mr. Shintaro Asako CPA, 35
Chief Financial Officer, Principal Accounting Officer and VP |
N/A
| N/A | Mr. Masatsune Okajima , 41
Head of Japanese Office and VP |
$
287.00K | N/A | Dr. Joji Suzuki M.D., Ph.D, 47
Sr. VP of Fin. & Admin. |
N/A
| N/A | Dr. Kenneth W. Locke Ph.D., 54
Consultant |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.41% Nasdaq 
Profile
